Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR2A | P27037 | 1/20 | 0.46 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 3/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3460867 | 0.99 | ACVR2A (0.44) | ACVR2ATGFBR2NPC1RAB9AALDH1A1 | |
| SCHEMBL3460789 | 0.79 | PLK1 (0.50) | ATRPIK3CDPIK3CAPIK3CGPRKDC | |
| SCHEMBL3461135 | 0.76 | PIK3CD (0.47) | ATRPIK3CDPIK3CAPIK3CGPRKDC | |
| SCHEMBL3459736 | 0.74 | ATR (0.56) | ATRPIK3CDPIK3CAPIK3CGPRKDC | |
| SCHEMBL3461940 | 0.74 | PIK3CD (0.59) | ATRPIK3CDPIK3CAPIK3CGPRKDC | |
| SCHEMBL3467024 | 0.73 | NPC1 (0.44) | NPC1RAB9AALDH1A1TP53MAPK1 | |
| SCHEMBL3462777 | 0.73 | ATR (0.51) | NPC1RAB9AALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL3461606 | 0.72 | ATR (0.55) | NPC1RAB9AALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL3462755 | 0.72 | ATR (0.51) | NPC1RAB9AALDH1A1SMN1; SMN2ATR | |
| SCHEMBL3461838 | 0.71 | ATR (0.55) | NPC1RAB9ATP53SMN1; SMN2ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | claimed |
| EP-1501514-B1 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7704995-B2 | Protein kinase modulators and methods of use | EXELIXIS, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| EP-1501514-A4 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20060211709-A1 | Protein kinase modulators and methods of use | EXELIXIS, INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1501514-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2005-02-02 | — | — | EP | disclosed |
| WO-2003093297-A2 | PROTEIN KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211709-A1 | Protein kinase modulators and methods of use | GRK2, MAP4K2, MAPKAPK2 | ACVR2A 2128/4885TGFBR2 3902/4885NPC1 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.